HUTCHMED Highlights FRUSICA-2 Registration Trial Data
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) is set to present significant results from the FRUSICA-2 registration clinical trial, detailing the effects of the combination of fruquintinib and sintilimab. This combination aims to provide effective treatment options for patients battling locally advanced or metastatic renal cell carcinoma. The presentation is scheduled during the European Society for Medical Oncology (ESMO) Congress.
Overview of the FRUSICA-2 Clinical Trial
The FRUSICA-2 trial is a randomized, open-label, active-controlled study focusing on the efficacy and safety of fruquintinib in combination with sintilimab, compared to standard treatments such as axitinib or everolimus. This study aims to improve patient outcomes in the second-line treatment landscape for advanced renal cell carcinoma. The trial involved 234 patients, who were allocated to receive either the investigational combination or mono therapy.
Key Findings from the Trial
Recent data has indicated that, at the cutoff for progression-free survival (PFS) analysis, patients treated with fruquintinib and sintilimab exhibited a median PFS of 22.2 months. In stark contrast, those on axitinib or everolimus achieved a median PFS of just 6.9 months. This signifies a substantial improvement in outcomes, showcasing the combination's effectiveness against advanced kidney cancer.
Statistical Analysis and Response Rates
The objective response rate (ORR) observed was an impressive 60.5% for patients on the fruquintinib and sintilimab regimen versus 24.3% in the axitinib/everolimus cohort. This demonstrated not only a higher likelihood of response but also a significantly longer duration of response (DoR), averaging 23.7 months compared to 11.3 months for the other standard treatment.
Safety and Tolerability of the Combination Therapy
The safety profile of the fruquintinib and sintilimab combination was considered tolerable, aligning with the individual profiles of each treatment component. Notably, treatment-emergent adverse events (TEAEs) of grade 3 or above were reported in 71.4% of patients within the combination therapy group, while 58.8% of patients in the standard treatment group experienced similar events.
Expert Insights on FRUSICA-2 Trial Outcomes
Professor Dingwei Ye from Fudan University Shanghai Cancer Center, co-leading principal investigator of the study, stated that the trial's results present robust evidence suggesting that this combination therapy could provide a crucial new treatment option for patients facing advanced renal cell carcinoma. The results reflect the potential benefits across diverse patient populations and prognostic risk groups.
Future Treatment Strategies
Furthermore, Professor Zhisong He from Peking University First Hospital emphasized that the FRUSICA-2 study outcomes could significantly influence second-line treatment strategies for this challenging condition, highlighting the combination's ability to enhance clinical outcomes for patients.
Regulatory Advances and Drug Approval Process
Building on the promising data from FRUSICA-2, a New Drug Application (NDA) for the fruquintinib and sintilimab combination treatment for patients with locally advanced or metastatic renal cell carcinoma has been submitted to the China National Medical Products Administration (NMPA) for review. This marks a significant step towards making this innovative therapy available to those in need.
About Renal Cell Carcinoma
Kidney cancer has seen a notable rise in incidences globally, with an estimated 435,000 new patients diagnosed worldwide recently. In China alone, the figure was around 74,000, with renal cell carcinoma accounting for approximately 90% of kidney tumors. These statistics underscore the urgent need for improved treatment options.
Fruquintinib: Mechanism and Commercial Status
Fruquintinib operates as a selective oral inhibitor targeting vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, crucial for thwarting tumor angiogenesis. Co-developed in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE, fruquintinib has been approved for treating metastatic colorectal cancer and has shown promise in combination therapies.
About HUTCHMED
HUTCHMED, trading on Nasdaq/AIM: HCM and HKEX: 13, is an innovative biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies for cancer and immunological diseases. The company aims to transition drug candidates rapidly from in-house discovery to market, making impactful treatments available worldwide.
Frequently Asked Questions
What is the purpose of the FRUSICA-2 trial?
The FRUSICA-2 trial evaluates the efficacy and safety of fruquintinib in combination with sintilimab compared to standard treatments for advanced renal cell carcinoma.
What were the main findings from the trial?
The trial showed that the combination therapy significantly improved progression-free survival and overall response rates compared to standard treatment options.
Who were the investigators involved in FRUSICA-2?
Leading experts included Professor Dingwei Ye and Professor Zhisong He, both of whom emphasized the trial's potential impact on treatment strategies.
Is there regulatory progress for the combination therapy?
Yes, an NDA for the combination therapy has been submitted to the NMPA for review, marking a step towards its potential approval.
What is the significance of fruquintinib?
Fruquintinib is a significant oral inhibitor designed to impede tumor growth by targeting crucial VEGFR, illustrating its potential in cancer treatments.
